CIK 0001000694
- Large accelerated filer
NOVAVAX INC
Sign in to watch- Ticker
- NVAX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 222816046
- Phone
- +1 240-268-2000
- Business address
- 21 FIRSTFIELD RD, GAITHERSBURG, MD
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-03 | Jacobs John C President and CEO | Option exercise | +150,167 | 264,130 | ||
| 2026-03-03 | Jacobs John C President and CEO | Shares withheld for taxes | −69,288 | $9.49 | $658K | 225,680 |
| 2026-03-03 | Jacobs John C President and CEO | Option exercise · Restricted Stock Units | −150,167 | 300,333 | ||
| 2026-03-03 | O'Hara Elaine EVP, Chief Strategy Officer | Option exercise | +56,334 | 157,071 | ||
| 2026-03-03 | O'Hara Elaine EVP, Chief Strategy Officer | Shares withheld for taxes | −22,429 | $9.49 | $213K | 134,642 |
| 2026-03-03 | O'Hara Elaine EVP, Chief Strategy Officer | Option exercise · Restricted Stock Units | −56,334 | 112,666 | ||
| 2026-03-03 | Casey Mark J EVP, Chief Legal Officer | Option exercise | +37,500 | 101,445 | ||
| 2026-03-03 | Casey Mark J EVP, Chief Legal Officer | Shares withheld for taxes | −11,378 | $9.49 | $108K | 90,067 |
| 2026-03-03 | Casey Mark J EVP, Chief Legal Officer | Option exercise · Restricted Stock Units | −4,000 | 4,000 | ||
| 2026-03-03 | Draghia-Akli Ruxandra EVP, Research & Development | Option exercise | +26,667 | 34,876 | ||
| 2026-03-03 | Draghia-Akli Ruxandra EVP, Research & Development | Shares withheld for taxes | −11,313 | $9.49 | $107K | 23,563 |
| 2026-03-03 | Draghia-Akli Ruxandra EVP, Research & Development | Returned to the company · Restricted Stock Units | −26,667 | 53,333 | ||
| 2026-03-02 | Kelly James Patrick EVP, CFO and Treasurer | Grant or award · Non-statutory Stock Option NQ | +194,000 | 194,000 | ||
| 2026-03-02 | Draghia-Akli Ruxandra EVP, Research & Development | Grant or award · Non-Statutory Stock Option NQ | +139,500 | 139,500 | ||
| 2026-03-02 | Casey Mark J EVP, Chief Legal Officer | Grant or award · Non-Statutory Stock Option NQ | +152,000 | 152,000 | ||
| 2026-03-02 | Jacobs John C President and CEO | Grant or award · Non-Statutory Stock Option NQ | +551,500 | 551,500 | ||
| 2026-03-02 | O'Hara Elaine EVP, Chief Strategy Officer | Grant or award · 2026 Non-statutory Stock Option NQ | +177,500 | 177,500 | ||
| 2026-03-02 | Draghia-Akli Ruxandra EVP, Research & Development | Grant or award · Restricted Stock Units | +93,000 | 101,000 | ||
| 2026-03-02 | Draghia-Akli Ruxandra EVP, Research & Development | Grant or award · Non-Statutory Stock Opotion NQ | +139,500 | $9.09 | $1.3M | 139,500 |
| 2026-03-02 | Jacobs John C President and CEO | Grant or award · Restricted Stock Units | +367,500 | 367,500 |
Page 3 of 14 · 279 trades